Drug Profile

Amlodipine besylate controlled release - Overseas Pharmaceuticals

Alternative Names: Amlodipine besylate controlled release

Latest Information Update: 10 Feb 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Overseas Pharmaceuticals
Class Antihypertensives; Dihydropyridines; Ischaemic heart disorder therapies; Small molecules
Mechanism of Action Calcium channel modulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Preclinical Hypertension

Most Recent Events

04 Jan 2023 Preclinical trials in Hypertension in China (PO) before January 2023.
04 Jan 2023 Overseas Pharmaceuticals plans a phase I trial of amlodipine besylate controlled-release tablets for Hypertension (In volunteers) in China (PO) (NCT05667818)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com